First, identification of patients at higher risk of ICI-induced MG can be valuable, including analyzing both the demographic and therapeutic trends in presentation; for instance, MG-associated ophthalmoplegia is more prevalent in Asian patients with ICI-induced MG compared to White patients (43.75% versus 12.77%, respectively), and nivolumab has been found to be more associated with positive anti-AChR antibody assays than pembrolizumab despite both being PD-1 inhibitors [23,24,112,118,130]. Here, PDCD1 is linked to myasthenia gravis.